ABMD Stock Recent News
ABMD LATEST HEADLINES
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
There's a lot more ahead for these market giants.
Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.
The company is planting seeds for future growth.
The $16.6 billion acquisition shakes up MedTech.
Johnson & Johnson has outperformed the Dow so far this year.
A healthcare titan wants to acquire the medical technology specialist for a whopping $16.6 billion.
Marking its biggest deal in nearly six years, Johnson & Johnson ( JNJ , Financial) announced on Tuesday it is buying Abiomed Inc. ( ABMD , Financial) for $16.6 billion in a bid to boost its cardiovascular business even as its spins off its consumer health division.
Abiomed, Inc. (NASDAQ:ABMD ) Q2 2023 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Jessica Moore - Vice President of Investor Relations, Johnson & Johnson. Joaquin Duato - Chief Executive Officer, Johnson & Johnson Michael Joaquin - Chairman, President and Chief Executive Officer Ashley McEvoy - Executive Vice President and Worldwide Chairman, Medtech Johnson & Johnson Joe Wolk - Chief Financial Officer, Johnson & Johnson Conference Call Participants Joanne Wuensch - Citibank Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Jayson Bedford - Raymond James Terence Flynn - Morgan Stanley Operator Its now pleasure to turn the conference over Vice President of Investor Relations, Jessica Moore.
The deal would add heart pumps, a fast-growing part of the medical-device industry, to the J&J lineup.